Overall, HMGB2+ CD8+ T cell was predictive of poor HCC immunotherapy response and Hmgb2flox/flox;Cd4-Cre mice improved the efficacy of anti–PD-1 therapy. This evidence concerns the gene CD8A and hepatocellular carcinoma.